It is well known that heparin neutralization by prot amine results from the competitive binding of protamine with antithrombin III (ATIII) to heparin [6] . Because the binding between protamine and heparin is electrostatic and heparin binds ATIII via a small pentasaccharide sequence [7] , it is very likely that only a certain domain on protamine which encompasses an essential sequence for favorable electrostatic interaction may fully maintain heparin neutralization function. Since small peptides with low molecular weight are usually associated with diminished or devoid immunogenicity [8] , our hypothesis is that some low molecular weight protamine fragments derived from protamine may retain anti heparin activity but be devoid of immunogenicity and "cross linking" ability of the native protamine.
In this study, a protamine fragment, which fully maintains the heparin neutralization function of the par ent protamine but with much less toxicity, was obtained by enzymatic digestion of protamine. Heparin neutraliza tion activity and toxicity of this protamine fraction were examined both in vitro and in vivo. (169 IU/mg; average molecular weight of 13 kD), antithrombin III (ATIII), factor Xa, and chromogenic substrate S 2238 were obtained from Pharmacia Hepar Inc. (USA). Actin cephaloplastin was obtained from Dade (USA). Fresh frozen human plasma in citrate was obtained from the American Red Cross in Detroit (USA). Rats (Sprague-Dawley, 270 ± 23 g) and mice (ICR strain, 6 7 week old) were supplied by Harlan Dawley Co (USA).
MATERIALS AND METHODS

Materials
Preparation of LMWP. Thermolysin and protamine were mixed in a 1 : 100 ratio in PBS solution containing 20 mM CaCl 2 . The reaction mixture was incubated for 30 min at room temperature, followed by the addition of EDTA (50 mM) to quench the protease activity. Low molecular weight protamine mixture was fractionated on a heparin affinity column (HiTrap) attached to HPLC by using a linear NaCl gradient prepared by mixing solutions of PBS and 2 M NaCl. A total of five peptide fractions were observed. A pure peptide fragment (termed as LMWP), which accounts for most of the heparin neutral ization ability of low molecular weight protamine mix ture, was obtained and its sequence (VSRRRRRRGGR RRR) was confirmed by mass spectrum and amino acid composition analysis.
Determination of heparin neutralization ability of LMWP in vitro. Heparin neutralization ability of LMWP was measured in human plasma using the HEPTest ® clot ting assay. In brief, 15 µl of protamine or LMWP solution (20 200 µg/ml) was mixed with 100 µl of heparinized human plasma (1 U heparin/ml). A mixture of 15 µl of saline with 100 µl of heparinized human plasma (1 U heparin/ml) was taken as control. To the mixture, 100 µl of ATIII was added. After 2 min of incubation, 100 µl of RECALMIX ® (preheated to 37°C) was added, and the clotting time was measured immediately using a fibrome ter (Fibrosystem; Becton Dickinson Company, USA).
Determination of heparin neutralization ability of LMWP in vivo. Female Sprague-Dawley rats (mean weight 270 ± 23 g) were anaesthetized (50 mg/kg sodium pentobarbital) and a single jugular vein cannula was inserted into the right jugular vein. Blood (0.5 ml) was drawn as a control at 5 min after the injection of 0.4 ml saline. Heparin (25 U in 0.2 ml saline) was dosed intra venously and blood samples (0.4 ml) were drawn at 5 min after heparin injection. Right after that, 0.2 ml protamine (100 µg/100 g body weight) or LMWP (100 250 µg/100 g body weight) was injected intravenously at a period of 2 min. Blood (0.5 ml) was drawn at 5 min after protamine injection. Heparin activities in these rat plasmas were determined by activated partial thromboplastin time (APTT) test using a fibrometer (Fibrosystem; Becton Dickinson Company).
Immunogenicity assay of LMWP in mice. The immunogenicity of protamine and LMWP was examined in mice. The production of polyclonal antibodies was per formed according to the method of Cooper and Paterson [9] . Twenty six ICR mice (6 7 week old), 12 for prota mine and 14 for LMWP, were included in this study. Each mouse was immunized with 50 µg of protamine or LMWP in complete Freund's adjuvant (CFA). The first booster was given at the fourth week after primary immunization with 5 µg of protamine (or LMWP) in incomplete Freund's adjuvant (IFA). Animals were bled at 2 week intervals. Blood was collected, allowed to clot, and cen trifuged to collect serum.
Determination of LMWP mediated platelet count drop. Female Sprague-Dawley rats (mean weight 270 ± 23 g) were anaesthetized (50 mg/kg sodium pentobarbi tal) and a single jugular vein cannula was inserted into the right jugular vein. Blood specimens (0.09 ml) were obtained prior to heparin (10 IU/100 g body weight) administration, and 5 and 10 min after administration of protamine (100 µg/100 g body weight) or LMWP (250 µg/100 g body weight). Platelet count was deter mined using phase contrast microscopy.
Detection of anti protamine and anti LMWP anti bodies by ELISA. High binding 96 well ELISA plates were first coated with 100 µl of equivalent concentra tion of protamine or LMWP (100 µg/ml) in PBS/Tween 20 (pH 7.5) and allowed to incubate overnight at 4°C. The unbound protamine or LMWP was removed by draining the plate and washing 4 times with PBS/Tween 20. The remaining binding sites in the wells were blocked by incubating the plates with 120 µl/well PBS/Tween 20 containing 1.0% human serum albumin for 1 h at 37°C. Anti protamine and anti LMWP anti bodies in diluted serum of immunized mice were detected by the routine ELISA method using goat anti mouse IgG alkaline phosphatase as the detection anti body. In competitive ELISA, diluted serum was replaced with a fixed dilution of serum (100 times) con taining increasing concentrations (1 to 1000 µg/ml) of free protamine or LMWP.
RESULTS
A total of eight peptide fractions were obtained after passing of enzyme digested protamine mixture through a heparin column (Fig. 1a) . Since protamine neutralization of heparin results from its stronger heparin affinity than that of ATIII [7] , small protamine fractions with weaker heparin binding strength is predicted to be unable to neu tralize anticoagulant activity of heparin. In agreement with this assumption, small protamine fragments with low heparin affinity (peaks 1 7, eluted before 0.80 M NaCl concentration) showed hardly any heparin neutralization function (data not shown). Only peak number eight showed high heparin binding strength (eluted at about 0.95 M NaCl concentration) and accounted for most of the heparin neutralization ability of the enzyme digested protamine mixture (table) . The mass spectrum and amino acid composition analysis (Fig. 1b) containing a single peptide with the sequence of VSR RRRRRGGRRRR was from the C terminal of prota mine and was termed low molecular weight protamine (LMWP). Anti heparin assay results from both in vitro and in vivo experiments showed that although the dose required for complete heparin neutralization was about two times higher than that of protamine, this peptide fully maintained the heparin neutralization function of prota mine (table) .
It is known that protamine mediated toxicities are mainly through an immunoglobulin mediated pathway because of the production of anti protamine antibodies [3, 4] . Since a small peptide with 20 amino acids or less is usually associated with low immunogenicity, we further compared the immunogenicity of protamine and LMWP by monitoring anti protamine or anti LMWP antibody production in protamine or LMWP immunized mice. As shown in Fig. 2 , antibody titers in pooled sera from prot amine immunized mice were much higher than those from LMWP immunized mice over the entire experi mental duration (8 weeks). The greatest difference in antibody production between these two groups was observed six weeks after the primary immunization, and the antibody level in LMWP immunized mice was three times lower than that in protamine immunized mice (Fig. 2) . The cross reactivity of anti protamine and anti LMWP to LMWP and protamine was also examined.
Although anti LMWP showed a slightly higher reactivity to protamine than LMWP, anti protamine exhibited much lower cross reactivity to LMWP (Fig. 3) . Protamine mediated adverse responses via the non immunologic pathway are attributed to the "cross link ing" ability of protamine due to its polycationic and poly meric nature. Either protamine or its complex with heparin can bind to molecules on the cell membrane and thus affect cell function [5] . For example, the binding of protamine or protamine/heparin complexes to platelets has proved to cause platelet aggregation and induce thrombocytopenia [10] . To examine if LMWP would cause less cross linking reactions as compared to its par ent protamine, the effect of LMWP on platelet aggrega tion and thrombocytopenia induction in mice was further tested by intravenous injection of LMWP in the presence or absence of heparin. As shown in Fig. 4a , protamine itself could cause a significant platelet count drop (~25%) during the period of 5 15 min after injection, but LMWP had hardly showed any such aggregation induction func tion during the same period. In agreement with this result, LMWP only induced about 10% of platelet count drop when it was used for heparin neutralization, but there was no statistical difference between LMWP and the control group (Fig. 4b) . On the contrary, protamine neu tralization of heparin caused more than 30% of platelet count drop under the same experimental conditions.
DISCUSSION
In spite of its Food and Drug Administration approval, adverse reactions of protamine sulfate range from mild hypotension to idiosyncratic fatal cardiac arrest because of its immunogenicity and "cross linking" ability. In fact, aside from its well known use in heparin neutral ization, protamine is used widely in insulin formulations to produce long acting insulin (neutral protamine Hagedorn (NPH) and protamine zinc insulin (PZI)) allowing insulin dependent diabetic patients to achieve euglycemia with less frequent insulin injections. This previous expo sure to protamine renders diabetic patients highly suscep tible to severe protamine hypersensitivity. It was reported 
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Note: Fig. 4. a) Comparison of platelet count drops in the blood of rats after intravenous injection of protamine (100 µg/100 g body weight) (1) and LMWP (250 µg/100 g body weight) (2) . Five, four, and two rats were used in protamine (1), LMWP (2) , and control (saline) (3) groups, respectively. Data represent the average of these experiments; * p < 0.05. b) Comparison of protamine (100 µg/100 g body weight) (1) and LMWP (250 µg/100 g body weight) (2) induced platelet count drops during its neutralization of heparin (10 IU/100 g body weight) in rats. Blood platelet numbers were measured at 5 min (P5) and 10 min (P10) after protamine or LMWP injection following the heparin injec tion. Five rats were used for both protamine and LMWP group. Blood platelet levels before heparin injection (H0) were taken as controls (100%); * p < 0.01 (in comparison with LMWP group); ** p < 0.01 (in comparison with saline group (3)). that 30% of NPH treated diabetics had IgG anti prota mine antibodies, and the risk of a hemodynamically signif icant protamine reaction at the time of cardiac surgery in insulin dependent diabetics was approximately ten times higher than that in non diabetic controls [11] . For this rea son, protamine toxicity has drawn considerable attention recently and various protamine like peptides obtained by either chemical or recombinant synthesis methods have been tested as substitutes to protamine for their heparin anticoagulant neutralization activity [12 15 ]. However, except for the expensive platelet factor 4 (1 mg/US $2800), none of these peptides have proved to be safe for clinical use regardless of their heparin neutralization abilities.
Low molecular weight protamine (LMWP) that we obtained here fully maintains the heparin neutralization function of its parent protamine (table); it is less immunogenic than the parent protamine (Fig. 2) ; it lacks cross reactivity to anti protamine antibodies (Fig. 3) and had hardly any effect on platelet aggregation (Fig. 4) . Therefore, compared to protamine, LMWP possesses much less toxicity and is highly likely to become a new nontoxic heparin antagonist. Since anti protamine anti bodies exhibits very low cross reactivity to LMWP, the use of LMWP as a substitute for protamine in heparin reversal will enable a large population of diabetic patients which already have anti protamine antibodies in their bodies to avoid the risks of immunoglobulin mediated, fatal protamine responses. In fact, LMWP has also proved to be an ideal substitute for protamine in its formulation with insulin and in DNA condensation (data to be pub lished). Therefore, in addition to heparin neutralization, less toxic LMWP also possesses great potential for its applications in other pharmaceutical products such as insulin formulation and gene therapy.
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